GlycoDisplay to present at WORLDSymposium 2020 in Orlando
GlycoDisplay has identified a new concept, Long-Acting Glycodesign (LAGD), to improve enzymes for the treatment of rare genetic lysosomal diseases. In spring 2019 GlycoDisplay, together with researchers at the University of Copenhagen, published the first results of the LAGD concept for the treatment of Fabry disease in Nature Communications.
Now GlycoDisplay’s technology attracts international awareness. Most of the Company’s partner agreements are with American companies, and Weihua Tian, researcher at the University of Copenhagen and at GlycoDisplay, just received a Young Investigator Award to present the Long-Acting Glycodesign concept at WORLDSymposium 2020 in Orlando, USA. WORLDSymposium organise research within lysosomal diseases. Together with three academic groups, GlycoDisplay recently applied for a H2020 Synergy Grant, and the Company and a large European partner currently prepare a Eurostar application, which they will submit in 2020.